A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

BMF-500

Investigational Product

Trial Locations (23)

10467

RECRUITING

Montefiore Hospital - Moses Campus - BRANY - PPDs, The Bronx

11042

RECRUITING

Northwell Health Cancer Institute, New Hyde Park

14203

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

20155

RECRUITING

Virginia Cancer Specialists, Gainesville

27858

NOT_YET_RECRUITING

East Carolina University, Greenville

30322

RECRUITING

Winship Cancer Institute, Emory University, Atlanta

32224

RECRUITING

Mayo Clinic, Jacksonville

40536

RECRUITING

University of Kentucky - Markey Cancer Center, Lexington

44195

RECRUITING

Cleveland Clinic Hospital, Cleveland

55902

RECRUITING

Mayo Clinic, Rochester

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

60637

RECRUITING

University of Chicago Duchossois Center for Advanced Medicine (DCAM), Chicago

73104

RECRUITING

University of Oklahoma - Stephenson Cancer Center, Oklahoma City

75251

RECRUITING

Texas Oncology-PA USOR, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

85054

RECRUITING

Mayo Clinic, Phoenix

90095

RECRUITING

UCLA Department of Medicine, Los Angeles

91010

RECRUITING

City of Hope National Medical Center, Duarte

94143

RECRUITING

University of California, San Francisco, San Francisco

95817

RECRUITING

University of California, Davis, Sacramento

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

07601

RECRUITING

John Theurer Cancer Center, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biomea Fusion Inc.

INDUSTRY

NCT05918692 - A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | Biotech Hunter | Biotech Hunter